U.S. Vaccine Names

At a glance

This tables includes names and basic information for vaccines available in the U.S.

U.S. Vaccines: Table 1

(For Combination Vaccines, See Table 2)

Vaccine Trade Name Abbreviation Manufacturer Route Recommended Doses Approved Ages Comments
Adenovirus Adenovirus
Type 4 & Type 7		 Barr Labs Inc. Oral
(2 Tablets)		 1 17-50 years Live: Approved for military populations
Anthrax BioThrax AVA Emergent BioSolutions IM/SC 3 18-65 years Inactivated, Adj.
Cyfendus AVA Emergent Product Development IM 2 18-65 years Cell-free filtrate from avirulent strain, CPG 7909 Adj.: Approved for post exposure
Chikungunya Ixchiq CHIK-LA Valneva Austria GmbH IM 1 ≥18 years Live Attenuated. For ages ≥ 60 years, see Chikungunya Vaccines | Chikungunya Virus | CDC
Vimkunya CHIK-VLP Bavarian Nordic IM 1 ≥12 years Recombinant; virus-like particle vaccine
Cholera Vaxchora Bavarian Nordic Oral (Liquid) 1 2-64 years Live Attenuated
COVID-19 Comirnaty 1vCOV-mRNA Pfizer IM 1 ≥12 years mRNA
SPIKEVAX 1vCOV-mRNA ModernaTx IM 1 ≥12 years mRNA
Mnexspike 1vCOV-mRNA ModernaTx IM 1 ≥12 years mRNA
Nuvaxovid 1vCOV–aPS Novavax, Inc. IM 1 ≥12 years Recombinant, Adj.
Dengue Dengvaxia DEN4CYD Sanofi SC 3 6-16 years Live Recombinant
DTaP Daptacel DTaP Sanofi IM 5 6 weeks-6 years Inactivated, Adj.
Infanrix DTaP GlaxoSmithKline IM 5 6 weeks-6 years Inactivated, Adj.
Ebola Ervebo rVSVΔG-ZEBOV-GP Merck IM 1 ≥12 months Live attenuated, recombinant (replicating)
Haemophilus influenzae type b (Hib) ActHIB Hib (PRP-T) Sanofi IM 4 2 months-5 years Inactivated, Adj.
(Tetanus toxoid conjugate)
Hiberix Hib (PRP-T) GlaxoSmithKline IM 4 6 weeks-4 years Inactivated, Adj.
(Tetanus toxoid conjugate)
PedvaxHIB Hib (PRP-OMP) Merck IM 3 2-71 months Inactivated, Adj.
(Meningococcal conjugate)
Hepatitis A Havrix HepA GlaxoSmithKline IM 2 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Vaqta HepA Merck IM 2 Pediatric:
12 months-18 years
Adult: ≥19 years		 Inactivated, Adj.
Hepatitis B Engerix-B HepB GlaxoSmithKline IM 3 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Recombivax HB HepB Merck IM 3 Pediatric:
Birth-19 years
Adult: ≥20 years		 Recombinant, Adj.
Heplisav-B HepB Dynavax Technologies IM 2 ≥18 years Recombinant, Adj.
Herpes Zoster (Shingles) Shingrix RZV GlaxoSmithKline IM 2 ≥50 years Recombinant, Adj.
Human Papillomavirus
(HPV)		 Gardasil9 9vHPV Merck IM 2 or 3 9-45 years Recombinant, Adj.
ACIP recommends 9-26 years. SCDM for ages 27- 45 years.
Influenza Afluria IIV3 Seqirus IM 1 or 2 ≥6 months Inactivated
Afluria Quadrivalent IIV4 Seqirus IM 1 or 2 ≥6 months Inactivated
Fluad aIIV3 Seqirus IM 1 ≥65 years Inactivated, Adj.
Fluad Quadrivalent aIIV4 Seqirus IM 1 ≥65 years Inactivated, Adj.
Fluarix IIV3 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
Fluarix Quadrivalent IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
Flublok RIV3 Sanofi IM 1 ≥ 9 years Recombinant, Egg-Free
Flublok Quadrivalent RIV4 Sanofi IM 1 ≥18 years Recombinant, Egg-Free
Flucelvax ccIIV3 Seqirus IM 1 or 2 ≥6 months Cell-Culture, Egg-Free
Flucelvax Quadrivalent ccIIV4 Seqirus IM 1 or 2 ≥6 months Cell-Culture, Egg-Free
FluLaval IIV3 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
FluLaval Quadrivalent IIV4 GlaxoSmithKline IM 1 or 2 ≥6 months Inactivated
FluMist LAIV3 Medimmune Intranasal 1 or 2 2-49 years Live Attenuated
FluMist Quadrivalent LAIV4 Medimmune Intranasal 1 or 2 2-49 years Live Attenuated
Fluzone IIV3 Sanofi IM 1 or 2 ≥6 months Inactivated
Fluzone Quadrivalent IIV4 Sanofi IM 1 or 2 ≥6 months Inactivated
Fluzone
High-Dose		 HD-IIV3 Sanofi IM 1 ≥65 years Inactivated
Fluzone
High-Dose Quadrivalent		 HD-IIV4 Sanofi IM 1 ≥65 years Inactivated
Japanese encephalitis Ixiaro JE Valneva IM 2 ≥2 months Inactivated, Adj.
Measles, Mumps, Rubella M-M-R II MMR Merck SC or IM 2 ≥12 months Live Attenuated
Priorix MMR GlaxoSmithKline SC 2 ≥12 months Live Attenuated
Meningococcal Menveo MCV4
MenACWY-CRM		 GlaxoSmithKline IM 2 2 months-55 years Inactivated
(CRM197 conjugate)
ACIP recommends 2 months and older
MenQuadfi MCV4
MenACWY-TT		 Sanofi IM 2 ≥6 weeks Inactivated
(tetanus toxoid conjugate)
Trumenba MenB-FHbp Pfizer IM 2 or 3 10-25 years Recombinant, Adj.
ACIP recommends 10  years and older
Bexsero MenB-4C GlaxoSmithKline IM 2 or 3 10-25 years Recombinant, Adj.
ACIP recommends 10  years and older
Penbraya MenACWY-TT/MenB-FHbp Pfizer IM 2 10-25 years Inactivated
(tetanus toxoid conjugate)/Recombinant, Adj.
ACIP recommends 10  years and older
Penmenvy MenACWY-CRM/MenB-4C GlaxoSmithKline IM 2 10-25 years Inactivated
(CRM197 conjugate)/Recombinant, Adj.
ACIP recommends 10  years and older
Mpox and Smallpox Jynneos Mpox Bavarian Nordic SC 2 ≥18 years  Live attenuated, (non-replicating)
Pneumococcal Pneumovax 23 PPSV23 Merck IM or SC 1 ≥2 years Inactivated (Polysaccharide)
Prevnar 20 PCV20 Pfizer IM 4 (6 weeks – 15 months)
1 (≥18 years)		 ≥6 weeks Inactivated, Adj.
(CRM197 conjugate)
ACIP recommends less doses for catch-up vaccination in children and adolescents
Vaxneuvance PCV15 Merck IM 4 (6 weeks – 15 months)
1 (≥18 years)		 ≥6 weeks Inactivated, aluminum phosphate adjuvant
(CRM197 conjugate)
ACIP recommends less doses for catch-up vaccination in children and adolescents
Capvaxive PCV21 Merck IM 1 ≥18 years Inactivated (CRM197 conjugate)
Polio Ipol IPV Sanofi IM or SC 4 ≥6 weeks Inactivated
Rabies Imovax Rabies Sanofi IM 3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
RabAvert Bavarian Nordic IM 3 (pre-exposure)
5 (post-exposure)		 All ages Inactivated
Rotavirus RotaTeq RV5 Merck Oral (Liquid) 3 6-32 weeks Live  Attenuated
Rotarix RV1 GlaxoSmithKline Oral (Liquid) 2 6-24 weeks Live Attenuated
Respiratory Syncytial Virus Abrysvo RSVpreF Pfizer IM 1 Pregnant women
(irrespective of age) and
>18 years		 Recombinant
Arexvy RSVPreF3 GlaxoSmithKline IM 1 ≥50 years Recombinant, Adj.
mResvia mRNA-1345 Moderna IM 1 ≥18 years mRNA
Tetanus,
(reduced) Diphtheria		 Tenivac Td Sanofi IM 1 ≥7 years Inactivated, Adj.
TdVax Td Massachusetts Biological Labs IM 1 ≥7 years Inactivated, Adj.
Tetanus, (reduced) Diphtheria,
(reduced) Pertussis		 Boostrix Tdap GlaxoSmithKline IM 1 ≥10 years Inactivated, Adj.
Adacel Tdap Sanofi IM 1 10-64 years Inactivated, Adj.
ACIP recommends 10  years and older
Typhoid Typhim Vi Sanofi IM 1 ≥2 years Inactivated, (Polysaccharide)
Vivotif Bavarian Nordic Oral (Capsules) 4 ≥6 years Live Attenuated
Varicella Varivax VAR Merck IM or SC 2 ≥12 months Live Attenuated
Vaccinia (Smallpox) ACAM2000 Sanofi Percutaneous 1 All ages Live Attenuated
Yellow Fever YF-Vax YF Sanofi SC 1 ≥9 months Live Attenuated

U.S. Vaccines: Table 2

(Combination Vaccines)

Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages Comments
Vaccine Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages Comments
DTaP, Polio Kinrix DTaP-IPV GlaxoSmithKline IM 1 4-6 years Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.
Quadracel DTaP-IPV Sanofi IM 1 4-6 years Inactivated, Adj.: Approved as 5th DTaP and 4th IPV.
DTaP, Hepatitis B, Polio Pediarix DTaP-HepB-IPV GlaxoSmithKline IM 3 6 weeks-6 years Inactivated, Adj.: Approved for 2, 4, 6 month doses.
DTaP, Polio, Haemophilus influenzae type b Pentacel DTaP-IPV/Hib Sanofi IM 4 6 weeks-4 years Inactivated, Adj.: Approved for 2, 4, 6, 15-18 month doses.
DTaP, Polio, Haemophilus influenzae type b, Hepatitis B Vaxelis DTap-IPV-Hib-HepB Sanofi IM 3 6 weeks-4 years Inactivated/ Inactivated (Meningococcal conjugate)/Recombinant, Adj
Hepatitis A, Hepatitis B Twinrix HepA-HepB GlaxoSmithKline IM 3 ≥18 years Inactivated/Recombinant, Adj.
Pediatric HepA + Adult HepB
Measles, Mumps, Rubella, Varicella ProQuad MMRV Merck SC 2 12 months-
12 years		 Live Attenuated

Other Immunizing Agents: Table 3

(Monoclonal Antibody Products for Routine Immunization)

Monoclonal Antibody Trade Name Abbreviation Manufacturer Route Doses in Routine Series Approved Ages Comments
Nirsevimab Beyfortus™ RSV-mAb AstraZeneca and Sanofi IM 1 ≤24 months Respiratory syncytial virus monoclonal antibody
Clesrovimab ENFLONSIA clesrovimab-cfor Merck IM 1 ≤12 months Respiratory syncytial virus monoclonal antibody

Notes

  • The abbreviations on this table (Column 3) were standardized jointly by staff of the Centers for Disease Control and Prevention, ACIP Work Groups, the editor of the Morbidity and Mortality Weekly Report (MMWR), the editor of Epidemiology and Prevention of Vaccine-Preventable Diseases (the Pink Book), ACIP members, and liaison organizations to the ACIP. These abbreviations are intended to provide a uniform approach to vaccine references used in ACIP Recommendations and Policy Notes published in the MMWR, the Pink Book, and the American Academy of Pediatrics Red Book, and in the U.S. immunization schedules for children, adolescents, and adults. In descriptions of combination vaccines, a hyphen (-) indicates products in which the active components are supplied in their final (combined) form by the manufacturer; a slash ( / ) indicates products in which active components must be mixed by the user.
  • "Doses in a Routine Series" (Column 6) reflects doses administered to a healthy patient at the recommended ages. It doesn't necessarily reflect schedules for patients with health conditions or other high-risk factors, alternative schedules, catch-up schedules, or booster doses not part of an initial series. For some combination vaccines, this column represents the routine number of doses for that product, and not necessarily the total number of doses in a complete series for the components. (For example, Kinrix® or Quadracel® may be used for only 1 dose of multi-dose DTaP and IPV series.)
  • "Adj." in the "Comments" column indicates that the vaccine contains an adjuvant.
  • A hyphen in an age range means "through" (i.e., "6 weeks-6 years" means 6 weeks through 6 years [to the 7th birthday]).

Additional Resources

Vaccines Licensed for Use in the United States (FDA)

Print
Content Source: